Overview

Management of Superficial Thrombophlebitis

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

Phase:

Phase 4

Details

Lead Sponsor:

University of Oklahoma

Collaborator:

Pfizer

Treatments:

Dalteparin
Heparin, Low-Molecular-Weight
Ibuprofen
Tinzaparin